Regeneron Invests $200M for 300M-Patient EHR Access, Secures 20-Week Eylea HD Approval
Regeneron secured exclusive access to TriNetX’s 300-million de-identified EHRs with a $200M investment to expand its RGC-linked genomic and proteomic database for AI-driven drug discovery. The FDA approved up to 20-week Eylea HD dosing, with 71% of wAMD and 72% of DME patients sustained ≥16-week intervals through 96 weeks.
1. Strategic Collaboration with TriNetX
Regeneron gains exclusive access to TriNetX’s phenotypic network of approximately 300 million de-identified patient records, including 170 million US profiles. The collaboration pairs these records with Regeneron Genetics Center’s genomic and proteomic cohorts under HIPAA and GDPR compliance. Regeneron will invest up to $200 million to expand its EHR-linked database and strengthen AI-driven research.
2. FDA Extends Eylea HD Dosing
The FDA has approved extended dosing for Eylea HD up to every 20 weeks after one year of response, based on 96-week data from the pivotal PULSAR (wAMD) and PHOTON (DME) trials. At week 96, 71% of wAMD patients and 72% of DME patients maintained dosing intervals of 16 weeks or longer, with 47% and 44% achieving 20-week intervals, respectively.
3. Implications for Regeneron's Pipeline and Commercial Outlook
Access to a larger, integrated health database is expected to accelerate target identification, biomarker validation and AI-powered therapeutic discovery, reinforcing Regeneron’s robust pipeline. Meanwhile, the extended Eylea HD regimen reduces treatment burden for patients and may drive higher compliance, adoption and revenue potential in the retina market.